U.S. markets open in 4 hours 11 minutes
  • S&P Futures

    4,253.25
    -33.25 (-0.78%)
     
  • Dow Futures

    33,778.00
    -203.00 (-0.60%)
     
  • Nasdaq Futures

    13,396.00
    -127.25 (-0.94%)
     
  • Russell 2000 Futures

    1,982.60
    -19.10 (-0.95%)
     
  • Crude Oil

    89.47
    -1.03 (-1.14%)
     
  • Gold

    1,767.80
    -3.40 (-0.19%)
     
  • Silver

    19.15
    -0.32 (-1.64%)
     
  • EUR/USD

    1.0090
    -0.0002 (-0.02%)
     
  • 10-Yr Bond

    2.8800
    0.0000 (0.00%)
     
  • Vix

    20.62
    +0.72 (+3.62%)
     
  • GBP/USD

    1.1884
    -0.0048 (-0.41%)
     
  • USD/JPY

    136.5140
    +0.6520 (+0.48%)
     
  • BTC-USD

    21,738.28
    -1,715.23 (-7.31%)
     
  • CMC Crypto 200

    516.25
    -41.48 (-7.44%)
     
  • FTSE 100

    7,529.13
    -12.72 (-0.17%)
     
  • Nikkei 225

    28,930.33
    -11.81 (-0.04%)
     

HC Wainwright Sees Agile Therapeutics' Twirla Tailwinds Post Roe-Wade Ruling

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Agile Therapeutics Inc's (NASDAQ: AGRX) Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that legalized abortion nationwide.

  • H.C. Wainwright expects prescription acceleration soon with non-retail channel ramping and Washington forcing coverage with the Affordable Care Act provisions assuring women straightforward, no-cost access to contraceptives.

  • The analyst has raised the price target to $5 from $2.50 and reiterated a Buy.

  • Related: Agile Therapeutics Tightens Q2 Forecast For Contraceptive Patch 'Twirla.'

  • Management indicates that Afaxys with meaningful institutional orders were likely also stirred by Roe. Large accounts, having switched to Twirla from high-dose Xulane, are still working down the remaining Xulane inventory.

  • The analyst thinks that if Twirla accelerates along with a lower cost-base, exiting this year, 2024 could potentially break even and re-rate the shares.

  • Also, additional consolidation in the revenue-generating women's health space, thus potential Agile strategic optionality.

  • Price Action: AGRX shares are down 3.70% at $0.66 during the market session on the last check Tuesday.

Latest Ratings for AGRX

Date

Firm

Action

From

To

Nov 2021

HC Wainwright & Co.

Maintains

Buy

Sep 2021

HC Wainwright & Co.

Maintains

Buy

Jul 2021

RBC Capital

Maintains

Outperform

View More Analyst Ratings for AGRX

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.